Investigation group | COX-2 inhibitor 3Â weeks | Control 3Â weeks | COX-2 inhibitor 6Â weeks | Control 6Â weeks |
---|---|---|---|---|
PGE-2 concentration in synovial fluid (pg/ml) | 3399.7 (± 3492.8) | 10,871.2 (± 4274.9) | 11,098.7 (± 7738.2) | 9920.7 (± 5815.4) |
*p = 0.018 |  | °p = 0.667 |  | |
3 wks vs 6 wks | p = 0.022 | p = 0.921 |  |  |
New bone area (mm2) | 5.09 (± 0.98) | 6.45 (± 1.23) | 6.55 (± 3.2) | 5.7 (± 2.39) |
A | *p = 0.028 |  | °p = 0.699 |  |
3 wks vs 6 wks | p = 0.302 | p = 0.439 |  |  |
New bone area (mm2) | 5.63 (± 0.98) | 5.55 (± 1.02) | 5.59 (± 1.34) | 4.75 (± 1.4) |
M | *p = 0.897 |  | °p = 0.317 |  |
3 wks vs 6 wks | p = 0.699 | p = 0.317 |  |  |
New bone area (mm2) | Â | Â | Â | Â |
A vs M | p = 0.123 | p = 0.028 | p = 0.345 | p = 0.398 |
Bone mineral density (mg HA/mm3) | 453.92 (± 41.85) | 504.23 (± 33.77) | 484.78 (± 63.61) | 465.04 (± 77.91) |
A | *p = 0.020 |  | °p = 0.731 |  |
3 wks vs 6 wks | p = 0.302 | p = 0.332 |  |  |
Bone mineral density (mg HA/mm3) | 231.57 (± 31.81) | 222.52 (± 33.31) | 216.76 (± 46.18) | 216.88 (± 40.25) |
M | *p = 0.414 |  | °p = 0.228 |  |
3 wks vs 6 wks | p = 0.651 | p = 0.475 |  |  |
Bone mineral density (mg HA/mm3) | Â | Â | Â | Â |
A vs M | p = 0.012 | p = 0.028 | p = 0.028 | p = 0.018 |
Failure load (N) | 69.33 (± 50.47) | 28.2 (± 20.89) | 37.4 (± 16.82) | 59.57 (± 53.6) |
Failure load (N) | *p = 0.171 |  | °p = 0.914 |  |
3 wks vs 6 wks | p = 0.240 | p = 0.394 |  |  |
Stiffness (N/mm) | 9.15 (± 5.64) | 5.24 (± 5.47) | 6.29 (± 3.79) | 10.68 (± 10.21) |
Stiffness (N/mm) | *p = 0.352 |  | °p = 0.762 |  |
3 wks vs 6 wks | p = 0.522 | p = 0.522 |  |  |